This disclosure relates to DNAzymes and biosensors for detecting pathogenic bacteria, and in particular, for detecting Legionella pneumophila. This disclosure also provides a method for detecting the presence of Legionella pneumophila in a test sample, comprising: a) contacting said test sample with the DNAzyme or biosensor described herein, wherein the DNAzyme comprises a detectable label; b) allowing cleavage of the DNAzyme if a target is present, thereby releasing the detectable label; and c) measuring a detectable signal if the portion of the DNAzyme comprising the detectable label is released, wherein the RNA cleavage activity of the DNAzyme is activated by a target from Legionella pneumophila.

Methods and kits for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating a bacterial infection, such as bacterial sinusitis, and one or more viruses indicating a viral infection, such as influenza.

Embodiments may include an automated method for evaluating a sepsis status associated with a blood sample obtained from an individual. Methods may include determining a standard deviation of monocyte volume associated with the blood sample. Methods may include determining a white blood cell count (WBC) associated with the blood sample. Methods may include evaluating, using a data processing module, the sepsis status associated with the blood sample. The data processing module may include a processor and a computer application. This computer application may cause the processor to compare the standard deviation of monocyte volume with a first cutoff value to provide a comparison. The computer application may cause the processor to compare the WBC to a second cutoff to provide a second comparison. The computer application may also cause the processor to evaluate the sepsis status associated with the blood sample based on the first comparison and the second comparison.

The present invention is directed to an aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more bacterial species from the genera Prevotella and Porphyromonas.

An apparatus is provided for airborne pathogen detection, which includes a crystal microbalance. The apparatus includes specific capture probes that are affixed to the crystal microbalance and are designed to bind to and capture a specific pathogen, such as a virus particle. This capture causes a change in mass of the crystal microbalance that can be detected. A method is provided for airborne pathogen detection, which includes calibrating a resonant frequency of the crystal microbalance to a mass on the crystal microbalance. The method also includes a step of conjugating the antibody to the crystal microbalance. The method also includes, for each measurement time, measuring a resonant frequency of the crystal microbalance and determining a mass change due to binding of the pathogen to the detector. This mass change is then related to pathogen load in the medium. A notification is output if the viral load exceeds a predetermined threshold.

The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.

The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.

The present disclosure provides a digital microfluidic (DMF) cartridge for performing a self-test for a target analyte, including a DMF cartridge comprising a bottom substrate and a top substrate separated by a droplet operations gap, wherein the bottom substrate comprises a plurality of droplet operations electrodes configured for performing droplet operations on a liquid droplet in the droplet operations gap; one or more reaction chambers or reaction zones on the bottom substrate that are supplied by an arrangement of the droplet operations electrodes, wherein each reaction chamber or reaction zone comprises at least one detection spot and is configured for performing a plasmonic particle-assisted ELISA (pELISA) for detection and quantification of a target analyte in a sample droplet. The device may include downloadable software for a self-test and be operable using a smart device.

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

The present disclosure includes methods and systems of detecting bacteria in a sample using phage-functionalized sensors, methods of enriching a sample with phage-functionalized magnetic particles, phage-functionalized magnetic particles and methods of making phage-functionalized magnetic particles.